|
Press Releases and Ad-hoc-Announcements 2008
December 19, 2008 |
|
MOLOGEN AG: EU grants EUR 3 million to develop DNA vaccine for humans
 more
|
November 13, 2008 |
|
MOLOGEN AG publishes results for the first nine months of 2008 and gives an overview of R&D activities
more
|
November 03, 2008 |
|
MOLOGEN AG receives patent for cell based gene therapy
more
|
August 13, 2008 |
|
MOLOGEN AG publishes results for the first half-year of 2008
more
|
July 16, 2008 |
|
MOLOGEN AG: First patient enrolled in clinical study with cancer therapy MGN1703
more
|
May 29, 2008 |
|
MOLOGEN AG prepares start of clinical study with cancer medicine MGN1703
more
|
May 14, 2008 |
|
Successful start to the 2008 financial year for MOLOGEN AG
more
|
May 05, 2008 |
|
MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
more
|
April 16, 2008 |
|
MOLOGEN AG explains voting rights announcements of the new major shareholders
more
|
March 27, 2008 |
|
MOLOGEN AG announces results for financial year 2007
more
|
March 26, 2008 |
|
MOLOGEN AG: Grant application achieves maximum score in EU funding program
more
|
January 21, 2008 |
|
MOLOGEN AG: Clarification of voting rights announcement from former Chief Executive Officer Prof. Burghardt Wittig
more
|
January 02, 2008 |
|
MOLOGEN AG: Supervisory Board Appoints Dr. Matthias Schroff as Chief Executive Officer
more
|
|
|
NEWSLETTER |
| To subscribe to our Newsletter please
 click here
|
|
|
PRESS
RELEASES 
